









市場行情
/
股票
/
nasdaq-uthr
/

United Therapeutics Corp

UTHR

483.230USD

-7.600-1.55%

收盤 01/09, 16:00（美東）報價延遲15分鐘

20.73B總市值

16.97本益比TTM



United Therapeutics Corp

483.230

-7.600-1.55%

概覽公司財務分析

概覽

公司

財務

分析

關於 United Therapeutics Corp 公司

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

United Therapeutics Corp簡介



公司代碼UTHR

公司名稱United Therapeutics Corp

上市日期Jun 17, 1999

CEORothblatt (Martine A)

員工數量1305

證券類型Ordinary Share

年結日Jun 17

公司地址1000 Spring St

城市SILVER SPRING

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編20910

電話13016089292

網址https://www.unither.com/

公司代碼UTHR

上市日期Jun 17, 1999

CEORothblatt (Martine A)

United Therapeutics Corp公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.59K

Ms. Jan Malcolm

Director

420.00

-100.00%

Mr. Raymond C. (Ray) Kurzweil, J.D.

Independent Director

Mr. Christopher A. Causey

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

Mr. Richard A. Giltner

Independent Director

20.57K

+1190.00%

Prof. Nilda Mesa, J.D.

Independent Director

5.29K

-187.00%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

+3200.00%

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+71.00%

收入明細

單位: USD更新時間: 1月6日週二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

其他

16.60M

2.08%

地區USD

名稱

營收

佔比

United States

774.80M

96.91%

Rest of World

24.70M

3.09%

業務

地區

業務USD

名稱

營收

佔比

Tyvaso DPI

336.20M

42.05%

Nebulized Tyvaso

141.80M

17.74%

Orenitram

131.10M

16.40%

Remodulin

125.90M

15.75%

Unituxin

47.90M

5.99%

其他

16.60M

2.08%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.22%

BlackRock Institutional Trust Company, N.A.

9.90%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

其他

65.68%

持股股東

佔比

The Vanguard Group, Inc.

10.22%

BlackRock Institutional Trust Company, N.A.

9.90%

Renaissance Technologies LLC

5.05%

Avoro Capital Advisors LLC

4.70%

State Street Investment Management (US)

4.47%

其他

65.68%

股東類型

持股股東

佔比

Investment Advisor

42.36%

Investment Advisor/Hedge Fund

33.75%

Hedge Fund

13.61%

Research Firm

2.96%

Pension Fund

2.92%

Individual Investor

1.84%

Bank and Trust

1.38%

Sovereign Wealth Fund

1.29%

Venture Capital

0.46%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

1381

42.69M

99.14%

-3.71M

2025Q3

1348

44.10M

102.42%

-3.87M

2025Q2

1338

46.42M

102.62%

-2.51M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

4.40M

10.22%

-31.08K

-0.70%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.26M

9.9%

-76.88K

-1.77%

Sep 30, 2025

Renaissance Technologies LLC

2.17M

5.05%

+54.30K

+2.56%

Sep 30, 2025

Avoro Capital Advisors LLC

2.02M

4.7%

-347.78K

-14.67%

Sep 30, 2025

State Street Investment Management (US)

1.92M

4.47%

-244.90K

-11.30%

Sep 30, 2025

Wellington Management Company, LLP

1.40M

3.25%

-44.16K

-3.06%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.25M

2.9%

+49.30K

+4.11%

Sep 30, 2025

AQR Capital Management, LLC

986.48K

2.29%

-286.68K

-22.52%

Sep 30, 2025

Darwin Global Management Ltd

748.55K

1.74%

+748.55K

Sep 30, 2025

LSV Asset Management

686.71K

1.59%

-177.91K

-20.58%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Health Care ETF

5.9%

Formidable Fortress ETF

4.22%

Franklin Genomic Advancements ETF

4.09%

First Trust NASDAQ Pharmaceuticals ETF

3.87%

Invesco Pharmaceuticals ETF

3.85%

Invesco Biotechnology & Genome ETF

3.82%

Invesco S&P MidCap Quality ETF

3.74%

Inspire Growth ETF

3.7%

VanEck Biotech ETF

3.58%

First Trust NYSE Arca Biotechnology Index Fund

3.4%

Simplify Health Care ETF

佔比5.9%

Formidable Fortress ETF

佔比4.22%

Franklin Genomic Advancements ETF

佔比4.09%

First Trust NASDAQ Pharmaceuticals ETF

佔比3.87%

Invesco Pharmaceuticals ETF

佔比3.85%

Invesco Biotechnology & Genome ETF

佔比3.82%

Invesco S&P MidCap Quality ETF

佔比3.74%

Inspire Growth ETF

佔比3.7%

VanEck Biotech ETF

佔比3.58%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.4%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

United Therapeutics Corp的前五大股東是誰？



United Therapeutics Corp的前五大股東如下：
The Vanguard Group, Inc.
持有股份：4.40M
佔總股份比例：10.22%。
BlackRock Institutional Trust Company, N.A.
持有股份：4.26M
佔總股份比例：9.90%。
Renaissance Technologies LLC
持有股份：2.17M
佔總股份比例：5.05%。
Avoro Capital Advisors LLC
持有股份：2.02M
佔總股份比例：4.70%。
State Street Investment Management (US)
持有股份：1.92M
佔總股份比例：4.47%。